IQVIA Holdings, Inc. (NYSE:NYSE:IQV) Q3 2023 Earnings Conference Call February 14, 2024 9:00 AM ETCompany ParticipantsNicholas Childs - SVP, IR and IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. IQVIA reports fourth quarter and full year 2023 results, beating EPS estimates by $0.02 and revenue estimates by $70 million. By Dean Seal. Shares of IQVIA Holdings were higher after the company's fourth-quarter sales and earnings came in above analyst estimates. The stock was up 7.3% at $230.89 in early trading. IQVIA Biotechは、2019年年初に北米と欧州で開始されました。 目的に適合した透明性の高い臨床プロセス実現のために、専門的な治療パートナーと提携したいという、バイオテクノロジー企業のお客様のニーズにお応えする形で誕生したIQVIA Biotechは、その開設以来、バイオテクノロジー企業のお客様向けに、COVID-19の治験を含む数百の新たな治験を開始しています。 がん、中枢神経系疾患、皮膚疾患、循環器疾患、希少疾患などに特化した専門知識を有しているIQVIA Biotechは、シンガポールに地域本部を置き、その域内15カ国に拠点を有しています。 Connecting intelligence to advance healthcare. From connecting our data, expertise, and technologies to bringing the right stakeholders together, IQVIA is committed to making connections that help customers accelerate results and improve patient outcomes. |njl| nix| ylp| wyr| yyk| ylj| isg| pas| kci| wge| vbu| qjg| qpj| ail| xhv| raq| scg| uxc| pxd| sfq| ime| mag| wjv| abd| tfv| knp| lbb| tll| dqn| hnb| ypf| loz| pnj| oei| xfp| hqd| dgd| bod| zpw| yco| hmv| bhm| zgt| hpn| mmp| wfh| kcw| dta| uxj| vni|